Hana Biosciences (HNAB.OB) Announces “Promising” Phase II Data for Adult Acute Lymphoblastic Leukemia Trials
Biopharmaceutical company Hana Biosciences focuses on enhancing cancer care. The company yesterday announced the completion of its phase II rALLY clinical trial for Marquibo for the treatment of adult acute lymphoblastic leukemia (ALL) in 65 patients, exceeding its previous target of 56 patients. "We would like to thank all the clinical investigators, patients and Hana employees whose efforts have allowed us to not only complete enrollment in our pivotal phase II rALLy trial, but exceed our enrollment target. Enrolling more than the targeted number of patients provides us with important pharmacokinetic data," Anne Hagey, M.D., chief medical officer of Hana…